Company overview
Signios Bio provides an integrated suite of multiomic technologies including genomics, transcriptomics, proteomics, epigenomics, metabolomics, microbiomics, and spatial biology, powered by a proprietary AI-driven bioinformatics platform. The company offers next-generation sequencing services such as whole-genome sequencing, whole-exome sequencing, single-cell RNA-seq, spatial transcriptomics, and long-read PacBio sequencing. These capabilities support pharmaceutical companies, biotech firms, and academic institutions in decoding disease biology, identifying biomarkers, and advancing precision medicine and drug discovery.
Signios Bio is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing, Software & Digital Lab partner serving United States & Americas. Core focus areas include signios bio, multiomics services, ngs sequencing, ai bioinformatics, single-cell rna-seq, precision medicine.
Industry categories: Diagnostics & Testing, Software & Digital Lab. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.signiosbio.com
- Categories
- Diagnostics & Testing, Software & Digital Lab
- Markets served
- United States & Americas
- Keywords
- signios bio, multiomics services, ngs sequencing, ai bioinformatics, single-cell rna-seq, precision medicine, drug discovery
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What multiomics and sequencing services does Signios Bio offer?
- Signios Bio offers whole-genome sequencing, whole-exome sequencing, bulk and single-cell RNA-seq, spatial transcriptomics, targeted NGS panels, ATAC-Seq, ChIP-Seq, bisulfite sequencing, TCR/BCR profiling, and long-read PacBio HiFi sequencing, alongside proteomics, epigenomics, metabolomics, and microbiomics powered by AI bioinformatics.
- What platforms does Signios Bio use for single-cell sequencing?
- Signios Bio is a 10x Genomics-certified provider using Chromium platforms for single-cell RNA-seq, immune profiling, single-nuclei sequencing, and ATAC-seq, plus BD Rhapsody platforms, with automated sample prep and AI analysis.
- How does Signios Bio support drug discovery and precision medicine?
- Signios Bio's AI-driven platform integrates multiomic data to decode complex disease biology, identify novel biomarkers, and accelerate discovery of targeted therapies and diagnostics for pharma, biotech, and academic researchers.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
